For research use only. Not for therapeutic Use.
MFI8 is a small molecule inhibitor of mitochondrial[1].
MFI8 (20 μM; 6 h) reduces significantly mitochondrial aspect ratio with an EC50 of 4.8 μM, and inhibits mitochondrial function via mitofusins and subsequently promoting mitochondrial fission[1].
MFI8 possesses functional groups that meet the criteria of the pharmacophore model to interact with mitofusins and promotes mitochondrial fission[1].
MFI8 binds to the HR2 domain of MFN2, modulates MFN conformation and complexes, and alters mitochondrial functionality[1].
MFI8 (0-20 μM; 6 h) concentration-responsively increases caspase-3/7 activity, induces cytochrome c release and decreases membrane potential in a mitofusin-dependent manner. MFI8 also induces DNA damage and induces cell death in combination with BV6 SMAC (second mitochondria-derived activator of caspases) mimetic[1].
| Catalog Number | I043351 |
| CAS Number | 694488-83-0 |
| Synonyms | 4-chloro-2-[1-(2,3-dimethylanilino)ethyl]phenol |
| Molecular Formula | C16H18ClNO |
| Purity | ≥95% |
| InChI | InChI=1S/C16H18ClNO/c1-10-5-4-6-15(11(10)2)18-12(3)14-9-13(17)7-8-16(14)19/h4-9,12,18-19H,1-3H3 |
| InChIKey | DYILWFVSLLZIIR-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=CC=C1)NC(C)C2=C(C=CC(=C2)Cl)O)C |
| Reference | [1]. Zacharioudakis E, et al. Modulating mitofusins to control mitochondrial function and signaling. Nat Commun. 2022 Jul 7;13(1):3775. |
